Krithika S Rao1, Alexander Aronshtam2, Keara L McElory-Yaggy2, Benjamin Bakondi1, Peter VanBuren2, Burton E Sobel2, Jeffrey L Spees3. 1. Cellular, Molecular and Biomedical Sciences Graduate Program, University of Vermont, Colchester, VT, USA Department of Medicine and Cardiovascular Research Institute, University of Vermont, 208 South Park Drive, Ste 2, Colchester, VT 05446, USA. 2. Department of Medicine and Cardiovascular Research Institute, University of Vermont, 208 South Park Drive, Ste 2, Colchester, VT 05446, USA. 3. Department of Medicine and Cardiovascular Research Institute, University of Vermont, 208 South Park Drive, Ste 2, Colchester, VT 05446, USA Stem Cell Core, University of Vermont, Colchester, VT 05446, USA jeffrey.spees@uvm.edu.
Abstract
AIMS: The aim of this study was to evaluate the paracrine activity of human epicardial-derived cells (hEPDCs) to screen for secreted vasoprotective factors and develop therapeutics to treat vascular reperfusion injury. METHODS AND RESULTS: Epicardial cells support cardiac development, repair, and remodelling after injury in part, through paracrine activity. We hypothesized that secreted ligands from hEPDCs would protect vascular integrity after myocardial infarction (MI) with reperfusion. During simulated ischaemia in culture (24-48 h), concentrated hEPDC-conditioned medium (EPI CdM) increased survival of primary cardiac endothelial cells. In a rat MI model, EPI CdM treatment reduced vascular injury in vivo after reperfusion. By phospho-receptor tyrosine kinase (RTK) arrays, ELISA, and neutralizing antibody screens, we identified hepatocyte growth factor (HGF) as a key vasoprotective factor in EPI CdM. Unexpectedly, we observed that some of the HGF in EPI CdM formed complexes with polyclonal IgG. Following reperfusion, preparations of HGF/IgG complexes provided greater vascular protection than free HGF with IgG. HGF/IgG complexes localized to blood vessels in vivo and increased HGF retention time after administration. In subsequent screens, we found that 'related to tyrosine kinase' (RYK) receptor was phosphorylated after exposure of cardiac endothelial cells to HGF/IgG complexes, but not to free HGF with IgG. The enhanced protection conferred by HGF/IgG complexes was lost after antibody blockade of RYK. Notably, the HGF/IgG complex is the first 'ligand' shown to promote phosphorylation of RYK. CONCLUSION: Early treatment with HGF/IgG complexes after myocardial ischaemia with reperfusion may rescue tissue through vasoprotection conferred by c-Met and RYK signalling. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The aim of this study was to evaluate the paracrine activity of human epicardial-derived cells (hEPDCs) to screen for secreted vasoprotective factors and develop therapeutics to treat vascular reperfusion injury. METHODS AND RESULTS: Epicardial cells support cardiac development, repair, and remodelling after injury in part, through paracrine activity. We hypothesized that secreted ligands from hEPDCs would protect vascular integrity after myocardial infarction (MI) with reperfusion. During simulated ischaemia in culture (24-48 h), concentrated hEPDC-conditioned medium (EPI CdM) increased survival of primary cardiac endothelial cells. In a rat MI model, EPI CdM treatment reduced vascular injury in vivo after reperfusion. By phospho-receptor tyrosine kinase (RTK) arrays, ELISA, and neutralizing antibody screens, we identified hepatocyte growth factor (HGF) as a key vasoprotective factor in EPI CdM. Unexpectedly, we observed that some of the HGF in EPI CdM formed complexes with polyclonal IgG. Following reperfusion, preparations of HGF/IgG complexes provided greater vascular protection than free HGF with IgG. HGF/IgG complexes localized to blood vessels in vivo and increased HGF retention time after administration. In subsequent screens, we found that 'related to tyrosine kinase' (RYK) receptor was phosphorylated after exposure of cardiac endothelial cells to HGF/IgG complexes, but not to free HGF with IgG. The enhanced protection conferred by HGF/IgG complexes was lost after antibody blockade of RYK. Notably, the HGF/IgG complex is the first 'ligand' shown to promote phosphorylation of RYK. CONCLUSION: Early treatment with HGF/IgG complexes after myocardial ischaemia with reperfusion may rescue tissue through vasoprotection conferred by c-Met and RYK signalling. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Yoshitaka Iso; Krithika S Rao; Charla N Poole; A K M Tarikuz Zaman; Ingrid Curril; Burton E Sobel; Jan Kajstura; Piero Anversa; Jeffrey L Spees Journal: Stem Cells Date: 2014-03 Impact factor: 6.277
Authors: Buddhadeb Dawn; Adam B Stein; Konrad Urbanek; Marcello Rota; Brian Whang; Raffaella Rastaldo; Daniele Torella; Xian-Liang Tang; Arash Rezazadeh; Jan Kajstura; Annarosa Leri; Greg Hunt; Jai Varma; Sumanth D Prabhu; Piero Anversa; Roberto Bolli Journal: Proc Natl Acad Sci U S A Date: 2005-02-25 Impact factor: 11.205
Authors: J B Moss; J Xavier-Neto; M D Shapiro; S M Nayeem; P McCaffery; U C Dräger; N Rosenthal Journal: Dev Biol Date: 1998-07-01 Impact factor: 3.582
Authors: Krithika S Rao; Jessica E Kloppenburg; Taylor Marquis; Laura Solomon; Keara L McElroy-Yaggy; Jeffrey L Spees Journal: Stem Cells Date: 2022-03-16 Impact factor: 5.845
Authors: Benjamin Liebman; Claire Schwaegler; Andrea T Foote; Krithika S Rao; Taylor Marquis; Alexander Aronshtam; Stephen P Bell; Prospero Gogo; Richard R LaChapelle; Jeffrey L Spees Journal: Front Bioeng Biotechnol Date: 2022-02-28